Q1 2026 Management view CEO Bret Christensen said the quarter was shaped by the company’s operational work on clinic growth and support, but also by a voluntary recall-related disruption: “Over the ...

biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures ...

Bret Christensen Chief Financial Officer — Bob Peterson Investor Relations — Szymon Serowiecki Full Conference Call Transcript Operator: Good day, and welcome to the biote Corp. first quarter 2026 ...

(NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today ...

Represents an inventory impairment charge of $1.3 million related to the January 2026 voluntary recall of select lots of bioidentical hormone pellets shipped by Asteria Health between May 2025 and ...

Irving-based hormone therapy firm Biote Corp. will buy back nearly $77 million in stock to settle a lawsuit filed by the company's founder. The money will go to Gary Donovitz, who founded the company ...

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...

The founder of an Irving-based hormone optimization company is on a mission to take it back, saying executives he hired to protect it ended up hijacking it and diluting his ownership by nearly $220 ...